RINVOQ

For adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.

For adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well.

Proven in clinical studies, RINVOQ can relieve joint pain, swelling, and stiffness at 12 weeks.

Fast relief that can last

Many people saw fast results* as early as week 2: Bar graph showing 33% of people saw results on 15mg of RINVOQ versus 11% on placebo. The majority felt significant relief* at 12 weeks: Bar graph showing 57% of people felt relief on 15mg of RINVOQ versus 24% on placebo.

Relief even at 3 years

Most people still taking RINVOQ continued to see improvement in PsA symptoms* even at 3 years: Bar graph showing 81% of people saw improvement on 15mg of RINVOQ.

In this less rigorous part of the study, patients and physicians were aware of RINVOQ treatment, which may have influenced the results at 3 years.

Individual results may vary.

*20% improvement in PsA symptoms when used with or without csDMARDs. Doctors adjusted supportive PsA medicines as needed at week 16 or 36.

Proven in clinical studies for PsA, RINVOQ can:

Relieve swelling and tenderness in places like fingers, elbows, and toes

Stop irreversible joint damage to prevent further progression

Significantly reduce PsA fatigue to help you get through your day

Leave skin noticeably clearer for people with PsA skin plaques

See before and after pictures

RINVOQ can help people achieve Minimal Disease Activity—that can mean less joint pain, swelling, stiffness, and skin symptoms

RINVOQ is not approved to treat plaque psoriasis.

Select Important Safety Information

RINVOQ may cause serious side effects, including:

  • Serious Infections, Cancer and Immune System Problems, and Blood Clots.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Increased risk of major cardiovascular events, such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.

Safety Considerations

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below.

RINVOQ can leave skin

Clear or almost clear

75% skin clearance is possible with RINVOQ

Drag the yellow sliders to see the difference.

Illustration of PsA skin plaques on an elbow after treatment

After 4 months

Before

Illustration of PsA skin plaques on an elbow before treatment

Illustration of skin clearance for people with moderate to severe PsA skin plaques. Individual results may vary.

Illustration of PsA skin plaques on a knee after treatment

After 4 months

Before

Illustration of PsA skin plaques on a knee before treatment

Illustration of skin clearance for people with moderate to severe PsA skin plaques. Individual results may vary.

RINVOQ has not been studied in and is not indicated for the treatment of plaque psoriasis.

Have you ever been prescribed a TNF blocker for psoriatic arthritis (PsA)?

Yes, I've been prescribed a TNF blocker

If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or ENBREL®, RINVOQ, a JAK inhibitor, works differently and may help.

What is RINVOQ? >

No, I haven't

There are many PsA treatment options that work in different ways. If you haven't seen improvement in your PsA symptoms, it may be time discuss options with your rheumatologist.

PsA Treatment Options >

I'm not sure

There are many PsA treatment options that work in different ways. If you're not sure what type of medication you're currently taking, it's important to ask your rheumatologist. If you haven’t seen improvement in your PsA symptoms, it may be time to discuss options with your rheumatologist.

PsA Treatment Options >

Not yet diagnosed

If you believe you're experiencing PsA symptoms, it's important to see a rheumatologist to be evaluated. If you’re diagnosed, you and your rheumatologist can work together to create a treatment plan that meets your personal needs.

Find a Rheumatologist >

HUMIRA® and ENBREL® are examples of TNF blockers. ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.

How do your PsA symptoms impact you?

Use the PsA Symptom Self-Assessment to take action, work with your doctor, and find the right treatment for you.

Understanding possible RINVOQ side effects

Consider the benefits and risks of taking RINVOQ to make an informed treatment choice with your rheumatologist.

NEXT PAGE

SUGGESTED FOR YOU

If PsA gets in the way of your favorite activities, setting treatment goals can help.